Skip to main content
PMC home page
Cancer Science logoLink to Cancer Science
. 2005 Aug 19;94(11):980–985. doi: 10.1111/j.1349-7006.2003.tb01388.x

Nuclear receptor DAX‐1 in human common epithelial ovarian carcinoma: An independent prognostic factor of clinical outcome

Manar Abd‐Elaziz 1,✉, Jun‐ichi Akahira 2, Takuya Moriya 1, Takashi Suzuki 1, Nobuo Yaegashi 2,1, Hironobu Sasano 1
PMCID: PMC11160189  PMID: 14611675

Abstract

DAX‐1 is a member of the nuclear receptor superfamily and is thought to be involved in the regulation of steroidogenesis. Its expression has been detected primarily in endocrine neoplasms such as adrenocortical as well as pituitary tumors in human, but its biological roles have not been examined well in sex steroid‐dependent neoplasms. The aim of this study is to detect the expression of DAX‐1 in common epithelial ovarian carcinomas in order to evaluate its possible biological significance. DAX‐1 immunoreactivity was examined using immunohistochemistry. The correlation between the status of DAX‐1 immunoreactivity and clinicopathological parameters and disease‐free survival of the patients in a series of 60 cases of common epithelial ovarian carcinoma was examined. The status of DAX‐1 immunoreactivity was evaluated using H score. DAX‐1 immunoreactivity was widely detected in the nuclei of common epithelial ovarian carcinoma cells. There was a significant positive correlation between DAX‐1 immunoreactivity and clinical staging (P=0.0241), tumor grade (P=0.0115), the residual size of the tumor (P=0.0014) and Ki‐67 labeling index (P=<0.0001). In univariate survival analysis, a significant association was detected between DAX‐1 immunoreactivity and shortened patient survival (P=0.0157). Other significant prognostic parameters were clinical stage, residual size of tumor and Ki‐67. In multivariate analysis, DAX‐1 immunoreactivity, clinical stage, residual size of tumor and Ki‐67 all turned out to be independent prognostic factors for shortened survival. In conclusion, DAX‐1 immunoreactivity is considered to be a new independent marker of poor prognosis or adverse clinical outcome in patients with epithelial ovarian carcinoma, possibly through altering in situ steroids production.

References

  • 1. Friedlander ML, Dembo AJ. Prognostic factors in ovarian cancer. Semin Oncol 1991; 18: 205–12. [PubMed] [Google Scholar]
  • 2. Akahira J, Yoshikawa H, Shimizu Y, Tsunematsu R, Hirakawa T, Kuramoto H, Shiromizu K, Kuzuya K, Kamura T, Kikuchi Y, Kodama S, Yamamoto K, Sato S. Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecol Oncol 2001; 81: 398–403. [DOI] [PubMed] [Google Scholar]
  • 3. Kaufmann M, Von Minckwitz G, Kuhn W, Schmid H, Costa S, Goerttler K, Bastert G. Combination of new biologic parameters as prognostic index in epithelial ovarian carcinoma. Int J Gynecol Cancer 1995; 5: 49–55. [DOI] [PubMed] [Google Scholar]
  • 4. Sevelda P, Denison U, Schemper M, Spona J, Vavra N, Salzer H. Oestrogen and progesterone receptor content as a prognostic factor in advanced epithelial ovarian carcinoma. Br J Obestet Gynecol 1990; 97: 706–12. [DOI] [PubMed] [Google Scholar]
  • 5. Akahira J, Suzuki T, Ito K, Kaneko C, Darnel AD, Moriya T, Okamura K, Yaegashi N, Sasano H. Differential expression of progesterone receptor isoforms A and B in the normal ovary, and in benign, borderline, and malignant ovarian tumors. Jpn J Cancer Res 2002; 93: 807–15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Cooper BC, Sood AK, Davis CS, Ritchie JM, Sorosky JI, Anderson B, Buller RE. Pre operative CA125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstet Gynecol 2002; 100: 59–64. [DOI] [PubMed] [Google Scholar]
  • 7. Zanaria E, Muscatelli F, Bardoni B, Strom TM, Guioli S, Guo W, Lalli E, Moser C, Walker AP, McCabe ER, Meitinger T, Monaco AP, Sassone‐Corsi P, Camerino G. An unusual member of nuclear hormone receptor superfamily responsible for X‐linked adrenal hypoplasia congenital. Nature 1994; 372: 635–41. [DOI] [PubMed] [Google Scholar]
  • 8. Tamai KT, Monaco L, Alastalo TP, Lalli E, Parvinen M, Sassone‐Corsi P. Hormonal and developmental regulation of DAX‐1 expression in Sertoli cells. Mol Endocrinol 1996; 10: 1561–9. [DOI] [PubMed] [Google Scholar]
  • 9. Ikeda Y, Swain A, Weber TJ, Hentges KE, Zanaria E, Lalli E, Tamai KT, Sassone‐Corsi P, Lovell‐Badge R, Camerino G, Parker KL. Steroidogenic factor 1 and DAX‐1 colocalize in multiple cell lineages: potential links in endocrine development. Mol Endocrinol 1996; 10: 1261–72. [DOI] [PubMed] [Google Scholar]
  • 10. Lalli E, Melner MH, Stocco DM, Sassone‐Corsi P. DAX‐1 blocks steroid production at multiple levels. Endocrinology 1998; 139: 4237–43. [DOI] [PubMed] [Google Scholar]
  • 11. Zazopoulos E, Lalli E, Stocco DM, Sassone‐Corsi P. DNA binding and transcriptional repression by DAX‐1 blocks steroidogenesis. Nature 1997; 390: 311–5. [DOI] [PubMed] [Google Scholar]
  • 12. Sugawara T, Lin D, Hoolt J, Martin KO, Javitt NB, Miller WL, Strauss JF 3rd. Structure of the human steroidogenic acute regulatory protein (StAR) gene: StAR stimulates mitochondrial cholesterol 27‐hydroxylase activity. Biochemistry 1995; 34: 12506–12. [DOI] [PubMed] [Google Scholar]
  • 13. Clark BJ, Wells J, King SR, Stocco DM. The purification, cloning and expression of a novel luteinizing hormone‐induced mitochondrial protein in MA‐10 mouse Leydig tumor cells. J Biol Chem 1994; 269: 28314–22. [PubMed] [Google Scholar]
  • 14. Lin D, Sugawara T, Strauss JF 3rd, Clark BJ, Stocco DM, Saenger P, Rogol A, Miller WL. Role of steroidogenic acute regulatory protein in adrenal and gonadal steroidogenesis. Science 1995; 267: 1828–31. [DOI] [PubMed] [Google Scholar]
  • 15. Stocco DM, Clark BJ. Regulation of acute production of steroid in steroidogenic tissue. Endocr Rev 1996; 17: 221–44. [DOI] [PubMed] [Google Scholar]
  • 16. Shibata H, Ikeda Y, Mukai T, Morohashi K, Kurihara I, Ando T, Suzuki T, Kobayashi S, Murai M, Saito I, Saruta T. Expression profiles of COUP‐TF, DAX‐1 and SF‐1 in the human adrenal gland and adrenocortical tumors: possible implication in steroidogenesis. Mol Genet Metab 2001; 74: 206–16. [DOI] [PubMed] [Google Scholar]
  • 17. Takayama K, Sasano H, Fukaya T, Morohashi K, Suzuki T, Tamura M, Costa MJ, Yajima A. Immunohistochemical localization of Ad4‐binding protein with correlation to steroidogenic enzyme expression in cycling human ovaries and sex cord stromal tumors. J Clin Endocrinol Metab 1995; 80: 2815–21. [DOI] [PubMed] [Google Scholar]
  • 18. Reinche M, Beuschlein F, Lalli E, Arlt W, Vay S, Sassone‐Corsi P, Allolio B. DAX‐1 expression in human adrenocortical neoplasms: implication for steroidogenesis. J Clin Endocrinol Metab 1998; 83: 2597–600. [DOI] [PubMed] [Google Scholar]
  • 19. Silverberg SG. Histological grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol 2000; 19: 7–15. [DOI] [PubMed] [Google Scholar]
  • 20. McCarty KS Jr, Miller LS, Cox EB, Konrath J, McCarty KS Sr. Estrogen receptor analyses: correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985; 109: 716–21. [PubMed] [Google Scholar]
  • 21. Suzuki T, Takahashi K, Darnel AD, Moriya T, Murakami O, Narasaka T, Takeyama J, Sasano H. Chicken ovalbumin upstream promoter transcription factor II in the human adrenal cortex and its disorders. J Clin Endocrinol Metab 2000; 85: 2752–7. [DOI] [PubMed] [Google Scholar]
  • 22. Sato Y, Suzuki T, Hidaka K, Sato H, Ito K, Ito S, Sasano H. Immuno‐localization of nuclear transcription factor, DAX‐1 and COUP‐TF II in the normal human ovary: correlation with Ad4BP/SF‐1 immuno‐localizatiom during the menstrual cycle. J Clin Endocrinol Metab 2003; 88: 3415–20. [DOI] [PubMed] [Google Scholar]
  • 23. Gurates B, Sebastian S, Yang S, Zhou J, Tamura M, Fang Z, Suzuki T, Sasano H, Bulun SE. WT1 and DAX‐1 inhibit aromatase P450 expression in human endometrial and endometriotic stromal cells. J Clin Endocrinol Metab 2002; 87: 4369–77. [DOI] [PubMed] [Google Scholar]
  • 24. Aylwin SJ, Welch JP, Davey CL, Geddes JF, Wood DF, Besser GM, Grossman AB, Monson JP, Burrin JM. The relation between steroidogenic factor 1 and DAX‐1 expression and in vitro gonadotropin secretion in human pituitary adenoma. J Clin Endocrinol Metab 2001; 86: 2476–83. [DOI] [PubMed] [Google Scholar]
  • 25. Ikuyama S, Mu YM, Ohe K, Nakagaki H, Fukushima T, Takayanagi R, Nawata H. Expression of an orphan nuclear receptor DAX‐1 in human pituitary adenomas. Clin Endocrinol 1998; 48: 647–54. [DOI] [PubMed] [Google Scholar]
  • 26. Key TJ. Hormones and cancer in humans. Mutat Res 1995; 333: 59–67. [DOI] [PubMed] [Google Scholar]
  • 27. Lindgren P, Backstrom T, Mahlck C, Ridderheim M, Cajander S. Steroid receptors and hormones in relation to cell proliferation and apoptosis in poorly differentiated epithelial ovarian tumors. Int J Oncol 2001; 19: 31–8. [PubMed] [Google Scholar]
  • 28. Langdon SP, Gabra H, Bartlett JM, Rabiaz GJ, Hawkins RA, Tesdale AL, Ritchie AA, Miller WR, Smyth JF. Functionality of progesterone receptor in ovarian cancer and its regulation by estrogen. Clin Cancer Res 1998; 4: 2245–51. [PubMed] [Google Scholar]
  • 29. Bu SZ, Yin DL, Ren XH, Jiang LZ, Wu ZJ, Gao QR, Pei G. Progesterone induces apoptosis and up regulation of p53 expression in human ovarian carcinoma cell lines. Cancer 1997; 79: 1944–50. [DOI] [PubMed] [Google Scholar]
  • 30. Rodrigues GC, Walmer DK, Cline M, Krigman H, Lessey BA, Whitaker RS, Dodge R, Hughes CL. Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis. J Soc Gynecol Invest 1998; 5: 271–6. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Science are provided here courtesy of Wiley

RESOURCES